2023
DOI: 10.1016/j.annonc.2023.04.110
|View full text |Cite
|
Sign up to set email alerts
|

P-54 Circulating immune cells as a tool to predict benefit from atezolizumab/bevacizumab in advanced hepatocellular carcinoma (aHCC)

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles